High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

• DOI: 10.1200/jco.1993.11.6.1132
• Publication Date: 2017-02-23T13:51:41Z
• Authors: W P Peters; M Ross; J J Vredenburgh; B Meisenberg; L B Marks; E Winer; J Kurtzberg; R C Bast; R Jones; E Shpall
• Keywords: Axillary lymph nodes; Carmustine

PURPOSE We studied high-dose cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) with autologous bone marrow support (ABMS) as consolidation after standard-dose adjuvant chemotherapy treatment of primary breast cancer involving 10 or more axillary lymph nodes. PATIENTS AND METHODS One hundred two women stage IIA, IIB, IIIA, IIIB nodes at surgery were registered; 85 eligible, treated, assessable. Patients treated four cycles doxorubicin, fluorouracil (CAF), followed by CPA/cDDP/BCNU ABMS. RESULTS Actuarial event-free survival for the study patients a median follow-up 2.5 years is 72% (95% confidence interval, 56% to 82%). Comparison three historical concurrent Cancer Leukemia Group B (CALGB) trials selected similar showed be between 38% 52%. Therapy-related mortality was 12%; pulmonary toxicity variable severity occurred in 31% patients. Quality-of-life evaluations indicate that are functioning well without major impairments. CONCLUSION High-dose ABMS CAF results decreased frequency relapse high-risk compared series years. Evaluation prospective, randomized trial warranted currently underway.